# Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

> **NCT06868238** · PHASE2 · RECRUITING · sponsor: **University of Florida** · enrollment: 30 (estimated)

## Conditions studied

- Ductal Carcinoma in Situ

## Interventions

- **DRUG:** Magtrace

## Key facts

- **NCT ID:** NCT06868238
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868238, "Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06868238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*